FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~April~~May 2011

Commission File Number: 001-34368

CHEMSPEC INTERNATIONAL LIMITED

No. 200, Wu Wei Road

Shanghai 200331

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

TABLE OF CONTENTS

Exhibit 99.1 – Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


CHEMSPEC INTERNATIONAL LIMITED

By:		/s/ Jianhua Yang
Name:		Jianhua Yang
Title:		Chief Executive Officer

Date: ~~April 12~~May 3, 2011

Exhibit 99.1

CHEMSPEC INTERNATIONAL LIMITED ~~ANNOUNCES FOURTH QUARTER AND FULL YEAR~~

~~2010~~FILES ~~UNAUDITED~~GOING-PRIVATE ~~FINANCIAL~~TRANSACTION ~~RESULTS~~STATEMENT ON SCHEDULE 13E-3

SHANGHAI, ~~April 11~~May 3, 2011 —– Chemspec International Limited (NYSE: CPC; “Chemspec” or the “Company”, incorporated in the Cayman Islands), a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced ~~its~~that ~~unaudited~~it ~~financial~~has ~~results1~~filed ~~for~~a going-private transaction statement on Schedule 13E-3 (“Going-Private Statement”) with the ~~fourth~~United ~~quarter~~States Securities and ~~full~~Exchange ~~year~~Commission ~~ended~~(“SEC”). ~~December 31~~Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement (the “Preliminary Proxy Statement”) that, ~~2010~~subject to completion, will be used in connection with an extraordinary general meeting of shareholders (the “EGM”), which the Company expects to hold in the third quarter of 2011.

~~Fourth~~As ~~Quarter~~described ~~2010~~more fully in the Going-Private Statement and the Preliminary Proxy Statement, the business to be transacted at the EGM includes shareholder ~~Financial~~approval ~~Highlights~~of the proposed merger and the agreement and plan of merger, dated as of March 21, 2011, by and among Halogen Limited (“Parent”), a Cayman Islands company beneficially owned by Dr. Jianhua Yang, chairman of the board of directors and chief executive officer of the Company, and Primavera Capital (Cayman) Fund I L.P., Halogen Mergersub Limited, a Cayman Islands company wholly owned by Parent, the Company and Dr. Jianhua Yang (the “Merger Agreement”). The proposed merger and the Merger Agreement are more fully described in the Going-Private Statement and the exhibits attached thereto, including the Preliminary Proxy Statement. In addition, a copy of the Merger Agreement is attached as an exhibit to the Preliminary Proxy Statement. If completed, the proposed merger would result in the Company becoming a privately held company and its ADSs would no longer be listed on the New York Stock Exchange. The Company’s board of directors, acting upon the unanimous recommendation of the independent committee formed by the board of directors, approved the Merger Agreement and resolved to recommend that the Company’s shareholders vote to adopt the Merger Agreement.

•The ~~Total~~Going-Private ~~sales~~Statement ~~reached~~and ~~RMB270.4~~the ~~million~~Preliminary Proxy Statement, and any amendments thereto, can be obtained from the SEC’s website (~~US$41~~http://www.~~0 million~~sec.gov). In addition, ~~representing~~shareholders anand ~~increase~~ADS ofholders ~~52.7%~~will ~~from~~receive the ~~fourth~~definitive ~~quarter~~proxy ofstatement ~~2009~~by mail and arequests ~~decrease~~for additional copies of ~~16.7%~~the ~~from~~definitive proxy statement should be directed to Okapi Partners LLC, the ~~third~~Company’s proxy ~~quarter~~solicitor, toll free at +1 855 208-8903 (or +1 212 297 0720 outside of ~~2010~~the United States). INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

•This ~~Gross~~announcement ~~profit~~is ~~totaled~~neither ~~RMB98.7~~a solicitation ~~million~~of ~~(US$15.0 million)~~proxy, an ~~increase~~offer ofto ~~56.6%~~purchase ~~from~~nor ~~the~~a ~~fourth~~solicitation ~~quarter~~ of ~~2009~~an offer to sell any securities and it is not a ~~decrease~~substitute offor ~~20.0%~~any ~~from~~proxy ~~the~~statement ~~third~~or ~~quarter~~other offilings ~~2010~~that have been or will be made with the SEC.

• Income from operations was RMB51.6 million (US$7.8 million), an increase of 80.4% from the fourth quarter of 2009 and a decrease of 39.9% from the third quarter of 2010.

• Net income attributable to the Company’s shareholders was RMB45.3 million (US$6.9 million), an increase of 30.3% from the fourth quarter of 2009 and a decrease of 35.7% from the third quarter of 2010.

• Basic and diluted earnings per ADS2 were both RMB1.26 (US$0.19). Basic and diluted earnings per ADS were both RMB0.96 (US$0.15) in the fourth quarter of 2009. Basic and diluted earnings per ADS in the third quarter of 2010 were RMB1.95 (US$0.29) and RMB1.94 (US$0.29), respectively.

Full Year 2010 Financial Highlights

• Total sales reached RMB1,082.0 million (US$163.9 million), an increase of 31.9% from RMB820.3 million in 2009.

• Gross profit was RMB417.2 million (US$63.2 million), an increase of 28.5% from RMB324.7 million in 2009.

• Income from operations was RMB266.7 million (US$40.4 million), an increase of 28.6% from RMB207.5 million in 2009.

• Net income attributable to the Company’s shareholders was RMB225.5 million (US$34.2 million), an increase of 30.8% from RMB172.4 million in the prior year.

• Basic and diluted earnings per ADS were both RMB6.24 (US$0.95), as compared with both being RMB5.18 (US$0.78) in the prior year.

Completion of Share Repurchase Program

The Company has substantially completed its share repurchase plan announced on September 22, 2010. The total funds used in the share repurchase plan were RMB11.0 million (US$1.6 million).

1 Certain Renminbi (RMB) amounts in this press release have been translated into U.S. dollar (USD) solely for the convenience of the reader. The conversion of RMB into USD in this release is based on the noon buying rate in the City of New York for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York on December 30, 2010, which was RMB 6.6000 to USD1.00. The percentages stated are calculated based on RMB.

2 1 ADS=60 ordinary shares

Dr. Jianhua Yang, Chairman and Chief Executive Officer of Chemspec, commented, “I am very pleased to announce our fourth quarter and full year financial results. In 2010, we set a new record that our sales passed the one-billion-RMB milestone. This is a testimony of our relentless effort in the year to expand our business development and strengthen the relationship with our customers, especially after the downturn of 2009.”

Dr. Yang continued, “In the fourth quarter of 2010, the total revenue grew 52.7% year over year and became the second highest in history for the same period of the year. With regard to the first quarter of 2011, our management estimates that our total sales to be between RMB205 and 210 million.”

Mr. Zixin Wang, Vice President of Finance, commented, “We came out of the trough in 2009 and achieved record-high sales in 2010. The total revenue was in line with our guidance announced in November 2010. During the year, we increased our R&D expenses to meet the higher expectations of our customers and expanded the production facilities to meet potential demand in future. In addition, as a result of a rise in the production and sales of more complex products, our inventories rose to RMB 470.4 million as of December 31, 2010 from RMB271.4 million as of December 31, 2009. We will implement a number of inventory control measures that strive to reduce the inventory level gradually in the near future.”

Fourth Quarter 2010 Financial Results

Total Sales

For the three months ended December 31, 2010, we generated total sales of RMB270.4 million (US$41.0 million), representing an increase of 52.7% from the fourth quarter of 2009 and a decrease of 16.7% from the third quarter of 2010. The increase from the fourth quarter of 2009 resulted from an increase in sales for chemicals used in both electronics and agrochemicals end-markets. The decrease in total sales compared to the third quarter of 2010 was mainly due to seasonally weakened sales in the electronics end-market.

Gross Profit and Gross Margin

In the fourth quarter of 2010, we generated gross profit of RMB98.7 million (US$15.0 million), representing an increase of 56.6% from the fourth quarter of 2009 and a decrease of 20.0% from the third quarter of 2010. We attribute the changes in the gross profit primarily to the corresponding fluctuations in the total sales in the corresponding quarters.

Our gross margin was 36.5% in the fourth quarter of 2010, as compared with 35.6% in the fourth quarter of 2009 and 38.0% in the third quarter of 2010. Compared with the fourth quarter of 2009, our gross margin increased slightly mainly because fewer inventories were written down in the fourth quarter of 2010. Compared to the third quarter of 2010, the decrease in our gross margin in the fourth quarter of 2010 was mainly due to the shift of the overall product mix.

Operating Expenses

Selling expenses and general and administrative expenses were RMB26.8 million (US$4.1 million), representing an increase of 13.5% from RMB23.6 million in the fourth quarter of 2009 and an increase of 16.7% from RMB23.0 million in the third quarter of 2010. We primarily attribute these increases in our general and administrative expenses to the increases in depreciation expenses for the Company’s new headquarters and increased consulting fees related to Sarbanes–Oxley (SOX) compliance.

Research and development (R&D) expenses were RMB22.1 million (US$3.4 million), representing an increase of 176.2% from RMB8.0 million in the fourth quarter of 2009 and an increase of 46.7% from RMB15.1 million in the third quarter of 2010. The increases in R&D expenses were due to a greater amount of material consumption expenses that were related to an increase in the number of active R&D projects.

Income from Operations and Earnings Before Income Taxes

As a result of factors mentioned above, income from operations was RMB51.6 million (US$7.8 million) and earnings before income taxes was RMB51.6 million (US$7.8 million), respectively, in the fourth quarter of 2010, representing increases of 80.4% and 77.6%, respectively, from the fourth quarter of 2009, and decreases of 39.9% and 39.1%, respectively, from the third quarter of 2010.

Net Income Attributable to Chemspec International Limited Shareholders

Net income attributable to Chemspec International Limited was RMB45.3 million (US$6.9 million), an increase of 30.3% from the fourth quarter of 2009 and a decrease of 35.7% from the third quarter of 2010. The changes mainly reflected the changes in the total sales in the corresponding periods.

Basic and diluted earnings per ADS were RMB1.26 (US$0.19), as compared to RMB0.96 (US$0.15) in the fourth quarter of 2009 and RMB1.95 (US$0.29) and RMB1.94 (US$0.29), respectively, in the third quarter of 2010.

Full Year 2010 Financial Results

Total Sales

For the year ended December 31, 2010, we generated total sales of RMB1,082.0 million (US$163.9 million), representing an increase of 31.9% from the year ended December 31, 2009. The increase was mainly due to the general recovery of the global business environment, especially an increase in demand for chemicals used in the electronics end-market.

Gross Profit and Gross Margin

Our gross profit was RMB417.2 million (US$63.2 million) for 2010, representing an increase of 28.5% from 2009. We attribute the increase in gross profit primarily to the corresponding increase in our total sales.

Our gross margin was 38.6% in 2010, as compared to 39.6% in 2009. We attribute the decrease in the gross margin primarily to price adjustments for certain products.

Operating Expenses

Selling expenses and general and administrative expenses were RMB88.9 million (US$13.5 million) in 2010, representing an increase of 9.6% from RMB81.1 million in 2009. We attribute this increase primarily to the increase in our depreciation expenses as a result of our new headquarters that started operations in the second half of 2009 and an increase in the amount of consulting fees related to Sarbanes-Oxley (SOX) compliance in 2010.

Research and development (R&D) expenses were RMB65.7 million (US$10.0 million) in 2010, representing an increase of 112.5% from RMB30.9 million in 2009. The increase in R&D expenses was due to a greater amount of material consumption expenses that were related to an increase in the number of active R&D projects to meet the anticipated demand from our customers.

Income from Operations and Earnings Before Income Taxes

For 2010, our income from operations was RMB266.7 million (US$40.4 million), representing an increase of 28.6% from RMB207.5 million in 2009.

Our earnings before income taxes was RMB265.2 million (US$40.2 million) in 2010, representing an increase of 28.8% from RMB206.0 million in 2009.

Net Income Attributable to Chemspec International Limited Shareholders

The net income attributable to Chemspec International Limited shareholders was RMB225.5 million (US$34.2 million), representing an increase of 30.8% from RMB172.4 million in 2009.

Basic and diluted earnings were both RMB6.24 (US$0.95), as compared to basic and diluted earnings of RMB5.18 (US$0.78) in 2009.

Cash Flows

As of December 31, 2010, we had RMB98.7 million (US$15.0 million) of cash, compared with RMB351.1 million as of December 31, 2009. Net cash outflows for 2010 mainly included capital expenditures of RMB248.7 million (US$37.7 million) for the expansion of production facilities.

First Quarter 2011 Guidance

Our management estimates that our total sales for the first quarter of 2011 to be between RMB205 and 210 million.

Conference Call Details

The Company will host a conference call and live webcast to discuss its fourth quarter financial results at 8:00 am Eastern Time (8:00 pm Shanghai time) on Monday, April 11, 2011.

The dial-in details for the live conference call are as follows:

- U.S. Toll Free Number:		+1-866-519-4004
- International Toll Free Dial-in Number:		+ 65-6723-9381
- Mainland China Domestic Number:		800-819-0121
- Mainland China Domestic Mobile		400-620-8038
- Hong Kong Toll Free Number:		800-930-346
Conference ID: CPC

A live and archived webcast of the conference call will be available in the Investor Relations section of Chemspec’s website at http://www.chemspec.com.cn.

A telephone replay of the call will be available from 11:00 pm Eastern Standard Time on April 11, 2011 through 11:59 pm Eastern Standard Time on April 17, 2011.

The dial-in details for the replay are as follows:

- U.S. Dial-in Number:		+1-866-214-5335
- International Dial-in Number:		+61-2-8235-5000
- China North Dial-in Number:		10-800-714-0386
- China South Dial-in Number:		10-800-140-0386
- Hong Kong Dial-in Number:		800-901-596
Conference ID: 48359124

Statement Regarding Unaudited Financial Information

The financial information set forth above is based on the Company’s unaudited interim consolidated financial statements and is subject to adjustments that may be identified by us and/or our auditors during the audit of our annual consolidated financial statements.

About Chemspec

Chemspec is a leading China-based contract manufacturer of highly engineered specialty chemicals, ~~especially,~~as ~~the~~well as fluorinated specialty chemicals. In manufacturing specialty chemicals, Chemspec also provides process design and process development services, which enable efficient and rapid production of specialty chemicals that are incorporated into the products of Chemspec’s end users. Chemspec’s customers and end users include electronics, pharmaceutical and agrochemical companies. For more information, please visit http://www.chemspec.com.cn.

SafeTable Harborof Statements Contents

~~This announcement contains forward~~Forward-~~looking~~Looking ~~statements.~~Statements These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in Chemspec’s filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1, as amended from time to time. Chemspec does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Statements about the expected timing, completion and effects of the proposed merger, and all other statements in this press release other than historical facts, constitute forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, each of which is qualified in its entirety by reference to the following cautionary statements. Forward-looking statements speak only as of the date hereof and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. A number of the matters discussed herein that are not historical or current facts deal with potential future circumstances and developments, in particular, whether and when the transactions contemplated by the Merger Agreement will be consummated and the expected date of the EGM. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from actual future experience involving any one or more of such matters. Such risks and uncertainties include: any conditions imposed on the parties in connection with consummation of the transactions described herein; approval of the proposed merger and adoption of the Merger Agreement by our shareholders; satisfaction of various other conditions to the closing of the proposed merger and the other transactions contemplated by the Merger Agreement; and the risks that are described from time to time in our reports filed with the SEC, including our Form 20-F for the year ended December 31, 2009. This press release speaks only as of its date, and we disclaim any duty to update the information herein.

For further information, please contact:

Chemspec International Ltd.

In Shanghai

Carol Fang

Manager, Investor Relations

Tel: +86-21-63638108

Email: ir@chemspec.com.cn

~~Table~~5 ~~of Contents~~

Chemspec International Limited

Unaudited Consolidated Balance Sheets

	December 31,2009RMB’000		December 31,2010RMB’000		December 31,2010USD’000
ASSETS
Current assets
Cash		351,097		98,719		14,957
Pledged bank deposits		37,919		56,746		8,598
Accounts receivable, net		94,154		137,873		20,890
Bills receivable		1,327		1,200		182
Inventories		271,434		470,432		71,278
Prepayment and other receivables		38,738		73,449		11,128
Amounts due from related parties		64		—		—
Deferred income tax assets		3,424		6,369		965
Total current assets		798,157		844,788		127,998
Property, plant and equipment, net		699,181		871,398		132,030
Land use rights		56,064		59,201		8,970
Intangible assets		839		730		111
Goodwill		7,446		7,446		1,128
Investment in an affiliate		13,296		12,793		1,938
Deferred income tax assets		300		—		—
Total assets		1,575,283		1,796,356		272,175
LIABILITIES AND EQUITY
Current liabilities
Bank borrowings		—		25,000		3,788
Accounts payable		81,870		142,319		21,564
Bills payable		49,738		64,340		9,748
Accrued expenses and other payables		183,266		148,238		22,461
Amounts due to related parties		23,659		5,559		842
Deferred income		—		14,215		2,154
Income taxes payable		1,298		5,408		819
Total current liabilities		339,831		405,079		61,376
Bank borrowings		10,000		—		—
Deferred income tax liabilities		18,056		21,517		3,260
Deferred income		15,136		3,280		497
Total liabilities		383,023		429,876		65,133
Equity
Chemspec International Limited shareholders’ equity
Ordinary shares:
Par value: HK$ 0.01; Authorized: 20,000,000,000 shares as of December 31, 2009 and December 31, 2010; Issued and outstanding: 2,167,620,000 shares as of December 31, 2009 and 2,163,190,740 shares as of December 31, 2010		21,686		21,649		3,280
Additional paid-in capital		323,916		319,048		48,341
Statutory reserves		63,422		85,820		13,003
Accumulated other comprehensive income		6,803		5,197		787
Retained earnings		770,425		929,108		140,774
Total Chemspec International Limited shareholders’ equity		1,186,252		1,360,822		206,185
Noncontrolling interests		6,008		5,658		857
Total equity		1,192,260		1,366,480		207,042
Total liabilities and equity		1,575,283		1,796,356		272,175

Chemspec International Limited

Unaudited Quarterly Consolidated Statements of Income

	Three-month periods ended
	December 31,2009 RMB’000			September 30,2010 RMB’000			December 31,2010 RMB’000			December 31,2010 USD’000
Sales		177,050			324,692			270,357			40,963
Cost of sales		(114,022	)		(201,248	)		(171,629	)		(26,004	)
Gross profit		63,028			123,444			98,728			14,959
Selling expenses		(2,817	)		(3,203	)		(3,083	)		(467	)
General and administrative expenses		(20,792	)		(19,767	)		(23,719	)		(3,594	)
Research and development expenses		(8,012	)		(15,080	)		(22,129	)		(3,353	)
Other operating expenses		(3,380	)		(121	)		(1,205	)		(183	)
Other operating income		236			242			351			53
Government grants		362			400			2,684			407
Income from operations		28,625			85,915			51,627			7,822
Other income (expenses):
Interest income		482			532			525			80
Interest expense		(309	)		—			—			—
Foreign currency exchange gain (loss), net		230			(1,625	)		(583	)		(88	)
Equity in loss of an affiliate		(91	)		(134	)		(150	)		(23	)
Other income		91			45			142			22
Earnings before income taxes		29,028			84,733			51,561			7,813
Income tax benefit (expense)		6,169			(14,210	)		(6,408	)		(971	)
Net income		35,197			70,523			45,153			6,842
Net (income) loss attributable to noncontrolling interests		(433	)		(122	)		141			21
Net income attributable to Chemspec International Limited shareholders		34,764			70,401			45,294			6,863
Basic earnings per share	RMB	0.02		RMB	0.03		RMB	0.02		USD	0.00
Diluted earnings per share	RMB	0.02		RMB	0.03		RMB	0.02		USD	0.00
Basic earnings per ADS	RMB	0.96		RMB	1.95		RMB	1.26		USD	0.19
Diluted earnings per ADS	RMB	0.96		RMB	1.94		RMB	1.26		USD	0.19

	Years ended
	December 31,2009 RMB’000			December 31,2010 RMB’000			December 31,2010 USD’000
Sales		820,295			1,082,031			163,944
Cost of sales		(495,584	)		(664,791	)		(100,726	)
Gross profit		324,711			417,240			63,218
Selling expenses		(11,245	)		(11,130	)		(1,686	)
General and administrative expenses		(69,871	)		(77,768	)		(11,783	)
Research and development expenses		(30,913	)		(65,679	)		(9,951	)
Other operating expenses		(7,145	)		(2,736	)		(415	)
Other operating income		953			1,624			246
Government grants		971			5,152			781
Income from operations		207,461			266,703			40,410
Other income (expenses):
Interest income		2,296			1,954			295
Interest expense		(2,149	)		(80	)		(12	)
Foreign currency exchange loss, net		(1,961	)		(3,249	)		(492	)
Equity in loss of an affiliate		(176	)		(503	)		(76	)
Other income		519			400			61
Earnings before income taxes		205,990			265,225			40,186
Income tax expense		(28,838	)		(38,999	)		(5,909	)
Net income		177,152			226,226			34,277
Net income attributable to noncontrolling interests		(4,721	)		(685	)		(104	)
Net income attributable to Chemspec International Limited shareholders		172,431			225,541			34,173
Basic earnings per share	RMB	0.09		RMB	0.10		USD	0.02
Diluted earnings per share	RMB	0.09		RMB	0.10		USD	0.02
Basic earnings per ADS	RMB	5.18		RMB	6.24		USD	0.95
Diluted earnings per ADS	RMB	5.18		RMB	6.24		USD	0.95

Chemspec International Limited

Unaudited Consolidated Statements of Cash Flows

	December 31,2009 RMB’000			December 31,2010 RMB’000			December 31,2010 USD’000
Cash flows from operating activities
Net income		177,152			226,226			34,277
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment		37,204			70,760			10,721
Land use rights expenses		1,132			1,315			199
Loss on disposal of property, plant and equipment		6,505			8,661			1,312
Amortization of intangible assets		108			109			17
Bad debt expense		64			(81	)		(12	)
Write-downs of inventories		14,696			7,296			1,105
Equity in loss of an affiliate		176			503			76
Gain on transfer of land use right to an affiliate		(290	)		—			—
Unrealized foreign exchange loss, net		92			255			39
Share-based compensation		15,443			1,499			227
Deferred income tax (benefit) expense		(644	)		816			124
Changes in operating assets and liabilities, net of effect of an acquisition
Pledged bank deposits related to purchase of inventories		994			(17,235	)		(2,611	)
Inventories		(67,867	)		(206,294	)		(31,256	)
Accounts receivable		42,354			(44,199	)		(6,697	)
Bills receivable		(1,327	)		127			19
Prepayment and other receivables		(14,141	)		(34,575	)		(5,239	)
Accounts payable		488			60,449			9,159
Bills payable related to purchase of inventories		(5,158	)		22,810			3,456
Accrued expenses and other payables		(2,202	)		(8,749	)		(1,326	)
Deferred income		9,570			2,359			357
Income taxes payable		(5,097	)		4,110			623
Net cash provided by operating activities		209,252			96,162			14,570
Cash flows from investing activities
Capital expenditures, including interest capitalized		(227,749	)		(248,697	)		(37,681	)
Pledged bank deposits related to purchase of property, plant and equipment		(17,377	)		(1,592	)		(241	)
Investment in an affiliate		(11,225	)		—			—
Non-interest bearing advances to related parties		(64	)		—			—
Non-interest bearing advances repaid by related parties		2,500			64			10
Payments for land use rights		(3,978	)		(4,452	)		(675	)
Net cash used in investing activities		(257,893	)		(254,677	)		(38,587	)

Cash flows from financing activities
Capital contributions to a subsidiary by noncontrolling shareholders	1,600		—		—
Cash distribution by a subsidiary to noncontrolling shareholders	(2,500	)	—		—
Dividends paid	—		(44,460	)	(6,735	)
Proceeds from issuance of ordinary shares upon IPO	389,022		—		—
Proceeds from exercise of share options	—		6,178		936
Issuance costs of ordinary shares upon IPO	(46,719	)	(3,028	)	(459	)
Acquisition of additional equity interest in subsidiaries from noncontrolling interests	(17,500	)	(51,300	)	(7,773	)
Proceeds from short-term bank borrowings	15,000		20,000		3,030
Repayments of short-term bank borrowings	(80,000	)	—		—
Proceeds from long-term bank borrowings	10,000		—		—
Repayment of long-term bank borrowings	—		(5,000	)	(758	)
Repurchase of ordinary shares	(8,134	)	(10,953	)	(1,660	)
Proceeds from non-interest bearing borrowings from related parties	6,000		—		—
Repayment of non-interest bearing borrowings from related parties	(47,687	)	(4,000	)	(606	)
Net cash provided by (used in) financing activities	219,082		(92,563	)	(14,025	)
Effect of foreign currency exchange rate changes on cash	54		(1,300	)	(197	)
Net increase (decrease) in cash	170,495		(252,378	)	(38,239	)
Cash at beginning of year	180,602		351,097		53,196
Cash at end of year	351,097		98,719		14,957
Supplemental disclosures of cash flow information:
Income taxes paid	34,579		34,073		5,163
Interest paid, net of amounts capitalized	2,149		80		12
Noncash investing and financing activities:
Accrued IPO cost	3,028		—		—
Payable for purchase of property, plant and equipment	118,174		129,323		19,594
Payable for acquisition of noncontrolling interest in Jiangsu Wei Er	23,500		—		—
Payable for acquisition of Kangpeng Nong Hua	25,000		—		—
Bills payable for purchase of property, plant and equipment	28,105		19,897		3,015
Land use right contributed to an affiliate	1,957		—		—

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

SafeTable Harborof Statements Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · Chemspec International Ltd